Vizionfocus (4771) is a TW-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of NT
1.5B, trading at NT
96.50 on the TAI. This SniperIQ fundamentals page covers Vizionfocus's valuation (P/E 15.1x, P/B 2.7x), profitability (net margin 21.2%), revenue (NT
.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapNT
1.5B
P/E (TTM)15.1x
Net Margin21.2%
Revenue (FY25)NT
.5B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Vizionfocus's market cap?
Vizionfocus (4771) has a market capitalization of approximately NT
1.5B, trading at NT
96.50 on the TAI. Market cap moves with the live share price.
What is Vizionfocus's P/E ratio?
Vizionfocus's trailing twelve-month P/E ratio is 15.1x, with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Vizionfocus?
Vizionfocus runs a net profit margin of 21.2%, a gross margin of 40.5%, and an operating margin of 28.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Vizionfocus generate?
Vizionfocus reported revenue of NT
.5B for fiscal year 2025, with net income of NT$741M and earnings per share (EPS) of 12.71. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Vizionfocus pay a dividend?
Vizionfocus offers a trailing dividend yield of about 2.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Vizionfocus financially healthy?
Vizionfocus carries a debt-to-equity ratio of 0.38x and a current ratio of 2.57x, with a market beta of 0.63. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Vizionfocus a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Vizionfocus (4771) the key facts are: market cap NT
1.5B, P/E 15.1x, revenue NT
.5B, 52-week range 167.5-221.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Vizionfocus's full fundamentals live
Get Vizionfocus's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.